Deufel Christopher L, Furutani Keith M, Dahl Robert A, Grams Michael P, McLemore Luke B, Hallemeier Christopher L, Neben-Wittich Michelle, Martenson James A, Haddock Michael G
Department of Radiation Oncology, Mayo Clinic, Rochester, MN.
Department of Radiation Oncology, Mayo Clinic, Rochester, MN.
Brachytherapy. 2018 Jul-Aug;17(4):718-725. doi: 10.1016/j.brachy.2018.03.006.
Cholangiocarcinoma patients who are potential candidates for liver transplantation may be treated with high-dose-rate (HDR) brachytherapy using a minimally invasive nasobiliary catheter in an effort to escalate the radiotherapy dose to the tumor and maximize local control rates. This work describes the equipment, procedures, and quality assurance (QA) that enables successful administration.
This work describes the nasobiliary catheter placement, simulation, treatment planning, treatment delivery, and QA. In addition, a chart review was performed of all patients who received endoscopic retrograde cholangiopancreatography for HDR bile duct brachytherapy at our institution from 2007 to 2017. The review evaluated how many patients were treated and the number of patients who could not be treated because of anatomic and/or equipment limitations.
From 2007 to 2017, 122 cholangiocarcinoma patients have been treated with HDR brachytherapy using a nasobiliary catheter. Three patients underwent catheter placement but did not receive brachytherapy treatment due to catheter migration between placement and treatment or because the HDR afterloader was unable to extend the source wire into the treatment site. Periodic QA is recommended for ensuring whether the HDR afterloader is capable of extending the source wire through an extensive and curved path.
Intraluminal HDR brachytherapy with a nasobiliary catheter can be successfully administered. Procedures and QA are described for ensuring safety and overcoming technical challenges.
对于可能适合肝移植的胆管癌患者,可使用微创鼻胆管导管进行高剂量率(HDR)近距离放射治疗,以提高肿瘤的放射治疗剂量并最大化局部控制率。本文介绍了实现成功治疗的设备、程序和质量保证(QA)。
本文介绍了鼻胆管导管放置、模拟、治疗计划、治疗实施和QA。此外,对2007年至2017年在本机构接受内镜逆行胰胆管造影以进行HDR胆管近距离放射治疗的所有患者进行了病历回顾。该回顾评估了接受治疗的患者数量以及因解剖和/或设备限制而无法治疗的患者数量。
2007年至2017年,122例胆管癌患者接受了使用鼻胆管导管的HDR近距离放射治疗。3例患者进行了导管放置,但由于放置与治疗之间导管移位或HDR后装治疗机无法将源线延伸至治疗部位而未接受近距离放射治疗。建议定期进行QA,以确保HDR后装治疗机能够将源线延伸通过一条广泛且弯曲的路径。
使用鼻胆管导管进行腔内HDR近距离放射治疗可以成功实施。文中描述了确保安全和克服技术挑战的程序及QA。